Erschienen in:
02.01.2021 | COVID-19 | Correspondence
Zur Zeit gratis
Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19
verfasst von:
Chia Siang Kow, Syed Shahzad Hasan
Erschienen in:
Rheumatology International
|
Ausgabe 3/2021
Einloggen, um Zugang zu erhalten
Excerpt
The comprehensive review by Misra et al. [
1] on the effects of antirheumatic drugs, including hydroxychloroquine, methotrexate and colchicine, in patients with coronavirus disease 2019 (COVID-19), along with discussion on their positive and negative sides to guide repurposing of these antirheumatic drugs against COVID-19, is commendable. Particularly, we read with interest the authors’ viewpoints regarding the potential therapeutic roles of colchicine in patients with COVID-19, and we would like to complement to their discussion on colchicine based on recent understandings on the pathophysiology of COVID-19. …